The International Society on Thrombosis and Haemostasis (ISTH) Treatment Guidelines suggests using CABLIVI for patients experiencing their first episode or another aTTP episode.
The ISTH created a guideline for the treatment of TTP, including aTTP. The guideline helps doctors and other healthcare professionals make informed treatment decisions for patients with aTTP. The ISTH is a global, not-for-profit organization of experts in this field. It has more than 5000 members in 100 countries.
CABLIVI was tested in a clinical study of adults with aTTP. It included 145 people with aTTP, of whom 72 received CABLIVI with plasma exchange and immunosuppressive therapy. The other 73 people received placebo (an injection without active medicine) with plasma exchange and immunosuppressive therapy.
Both groups received either treatment with CABLIVI or placebo during daily plasma exchange therapy and for 30 days after. Some people received treatment for an additional 28 days based on their doctor’s decision. After treatment was stopped, everyone was followed by their doctor for 28 more days.
Faster time to normal platelet count
87% of people in the CABLIVI group were free of aTTP-related events during the treatment period
Significantly fewer people had at least 1 of the following aTTP-related events in the CABLIVI group vs the placebo group (13% receiving CABLIVI [9 people] vs 49% receiving placebo [36 people]):
Four aTTP-related deaths happened during the trial, including 1 non–treatment-related death in the CABLIVI group during the treatment-free follow-up period and 3 deaths in the placebo group during the treatment period.
87% of people in the CABLIVI group did not have another episode of aTTP during treatment and for 28 days after
Significantly fewer people had another episode of aTTP that required starting plasma exchange again within the full study period in the CABLIVI group vs the placebo group (13% receiving CABLIVI [9 people] vs 38% receiving placebo [28 people]).
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.